Top > Search of International Patents > PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

Foreign code F170009075
File No. (S2015-2036-N0)
Posted date May 29, 2017
Country WIPO
International application number 2016JP081279
International publication number WO 2017073485
Date of international filing Oct 21, 2016
Date of international publication May 4, 2017
Priority data
  • P2015-211959 (Oct 28, 2015) JP
Title PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF
Abstract The present invention provides a novel peptide having the property of specifically accumulating in and directly acting on a glioma. The present invention is a peptide represented by any one of the following (a) to (c): (a) a peptide formed from an amino acid sequence that includes a sequence represented by any one of SEQ ID NOs: 1, 2, and 3; (b) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence having undergone deletion, substitution or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: 1, 2, and 3; and (c) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence at least 60% identical to a sequence represented by any one of SEQ ID NOs: 1, 2, and 3.
Outline of related art and contending technology BACKGROUND ART
The frequency of occurrence is primary brain tumors, 10 million people per year per 1 population are said to human 10-15, of which 1/4 of the total surface area referred to as glioma tumor (glioma) group. High-grade gliomas among group classified as astrocytoma (grade 3) and leaves the forming five-year survival rate of about 23% and 5, glioblastoma and 10% (grade 4) is significantly lower. As glioma brain tissue penetrates into the existing Vth_TR infiltration since the characteristics of the tumor lesions, diagnosis by biopsy to determine or craniotomy surgery, radiation therapy including as much as possible in the tumor boundary precise diagnostic information of the pathological lesion portion is required. The current with respect to the central nervous system disease (lesions in the brain) as image information can be provided the highest accuracy as a test or diagnostic method, for example, in combination with the contrast agent, computed tomography (Computed Tomography: CT), magnetic resonance imaging (Magnetic resonance imaging: MRI), positron emission tomography (Positron Emission Tomography: PET) and the inspection method of the method or the like. More precisely as a method for acquiring information image diagnosis, for example fluorodeoxyglucose (fluorodeoxy glucose: FDG) - PET method and the like.
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, requires the delivery of drug target selection to the treatment of malignant tumors (Drag Delivery System) apply the tool DDS, cause serious side effects in use difficult. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, neovascularization or existing in a blood vessel endothelial cells (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, alone or in combination with other pharmaceutical without simultaneous imaging agents in the form or have been applied as DDS (for example, see Patent Document 1.).
Scope of claims (In Japanese)[請求項1]
以下の(a)~(c)のいずれかのペプチド。
(a)配列番号1、2、3のいずれかで表される配列を含むアミノ酸配列からなるペプチド、
(b)配列番号1、2、3のいずれかで表されるアミノ酸配列において、1若しくは数個のアミノ酸が欠失、置換若しくは付加された配列を含むアミノ酸配列からなり、且つ、グリオーマに特異的な集積性を有するペプチド、
(c)配列番号1、2、3のいずれかで表される配列と同一性が60%以上である配列を含むアミノ酸配列からなり、且つ、グリオーマに特異的な集積性を有するペプチド
[請求項2]
L-アミノ酸からなるペプチドである請求項1に記載のペプチド。
[請求項3]
請求項1又は2に記載のペプチドをコードすることを特徴とする核酸。
[請求項4]
請求項3に記載の核酸を含むことを特徴とするベクター。
[請求項5]
請求項1又は2に記載のペプチドを含むことを特徴とするキャリア。
[請求項6]
さらに、標識物質又は修飾物質を備える請求項5に記載のキャリア。
[請求項7]
前記標識物質が、安定同位体、放射性同位体又は蛍光物質である請求項6に記載のキャリア。
[請求項8]
前記修飾物質が、糖鎖又はポリエチレングリコールである、請求項6又は7に記載のキャリア。
[請求項9]
請求項5~8のいずれか一項に記載のキャリアと生理活性物質とを備えることを特徴とする医薬組成物。
[請求項10]
グリオーマに起因する脳脊髄腫瘍治療用又は診断用である、請求項9に記載の医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • KONDO Eisaku
  • SAITO Ken
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close